{"id":"bcg-for-injection","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Dysuria (painful urination)"},{"rate":"40-50","effect":"Urinary frequency"},{"rate":"20-40","effect":"Hematuria (blood in urine)"},{"rate":"10-20","effect":"Fever"},{"rate":"10-15","effect":"Malaise/fatigue"},{"rate":"5-10","effect":"Nausea"},{"rate":"<1","effect":"BCG sepsis (rare but serious)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BCG works by activating innate and adaptive immune responses through toll-like receptor signaling and promoting Th1-type immunity. When instilled directly into the bladder, it triggers local immune activation that leads to infiltration of immune cells (macrophages, T cells, NK cells) that target and destroy urothelial cancer cells. This mechanism has been the gold standard for non-muscle-invasive bladder cancer treatment for decades.","oneSentence":"BCG (Bacillus Calmette-Guérin) is a live attenuated mycobacterial vaccine that stimulates the immune system to recognize and attack cancer cells, particularly in the bladder.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:48.086Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-muscle-invasive bladder cancer (NMIBC), high-grade or recurrent"},{"name":"Carcinoma in situ (CIS) of the bladder"}]},"trialDetails":[{"nctId":"NCT06833073","phase":"PHASE2","title":"A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-11","conditions":"Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ","enrollment":308},{"nctId":"NCT07483970","phase":"PHASE1","title":"A Phase I/II Study of JL19001 Injection Alone or in Combination With BCG in Subjects With High Risk Non-Muscle Invasive Bladder Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Jecho Biopharmaceuticals Co., Ltd.","startDate":"2026-03-30","conditions":"High Risk Non-muscle Invasive Bladder Cancer","enrollment":18},{"nctId":"NCT05547464","phase":"PHASE1, PHASE2","title":"Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2023-07-31","conditions":"Tuberculosis","enrollment":497},{"nctId":"NCT07206225","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-11-06","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":294},{"nctId":"NCT07424287","phase":"PHASE3","title":"A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-03","conditions":"NMIBC","enrollment":236},{"nctId":"NCT05537038","phase":"PHASE1","title":"Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2023-04-18","conditions":"Tuberculosis","enrollment":120},{"nctId":"NCT06845358","phase":"PHASE1","title":"Safety and Challenge Study of BCG TICE(R) Vaccination to Test Tuberculosis Immunity in Heathy Humans","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-11-26","conditions":"Tuberculosis","enrollment":""},{"nctId":"NCT05592223","phase":"PHASE1","title":"Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-12-06","conditions":"Tuberculosis","enrollment":20},{"nctId":"NCT02081326","phase":"PHASE2","title":"Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2015-06","conditions":"Diabetes Mellitus, Type One, Diabetes Mellitus, Type I, Autoimmune Diabetes","enrollment":150},{"nctId":"NCT05180591","phase":"PHASE2","title":"Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-03-22","conditions":"Diabetes Mellitus, Type 1, Diabetes type1, Autoimmune Diabetes","enrollment":150},{"nctId":"NCT05866536","phase":"PHASE2","title":"Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-05-04","conditions":"Diabetes Mellitus, Type 1 Diabetes, Diabetes type1","enrollment":100},{"nctId":"NCT06704191","phase":"PHASE1, PHASE2","title":"In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-04-21","conditions":"Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8","enrollment":40},{"nctId":"NCT05126472","phase":"PHASE1","title":"Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-11-08","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":55},{"nctId":"NCT07152639","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of EEC for the Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years and Above","status":"RECRUITING","sponsor":"Chengdu CoenBiotech Co., Ltd","startDate":"2025-08-09","conditions":"Tuberculosis","enrollment":1784},{"nctId":"NCT05539989","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa","status":"WITHDRAWN","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2025-12-31","conditions":"Tuberculosis, HIV Infections","enrollment":""},{"nctId":"NCT07094711","phase":"PHASE2","title":"Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG (BOOST)","status":"NOT_YET_RECRUITING","sponsor":"University of Virginia","startDate":"2025-09-30","conditions":"Mycobacterium Avium-intracellulare Infection, Mycobacterium Infections, Nontuberculous","enrollment":48},{"nctId":"NCT06971614","phase":"PHASE2","title":"A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC","status":"RECRUITING","sponsor":"ImmVira Pharma Co. Ltd","startDate":"2025-06-09","conditions":"Nonmuscle-invasive Bladder Cancer","enrollment":160},{"nctId":"NCT06714513","phase":"PHASE1","title":"ID93+GLA-SE Vaccine Against Tuberculosis in Older Adults Aged 55-74","status":"RECRUITING","sponsor":"Quratis Inc.","startDate":"2025-05-09","conditions":"Tuberculosis, Pulmonary","enrollment":144},{"nctId":"NCT06997367","phase":"PHASE2","title":"Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV169/2024)","status":"RECRUITING","sponsor":"Bharat Biotech International Limited","startDate":"2025-03-01","conditions":"Tuberculosis (TB)","enrollment":164},{"nctId":"NCT06438978","phase":"PHASE1","title":"Tuberculosis Vaccine in Healthy Indian Adults","status":"COMPLETED","sponsor":"Bharat Biotech International Limited","startDate":"2024-01-19","conditions":"Tuberculosis","enrollment":30},{"nctId":"NCT06873282","phase":"PHASE2","title":"Phase 2 Study of the ТВ/Flu-05Е Tuberculosis Vaccine","status":"COMPLETED","sponsor":"Research Institute of Influenza, Russia","startDate":"2023-12-13","conditions":"Tuberculosis","enrollment":160},{"nctId":"NCT04975178","phase":"PHASE3","title":"Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa","status":"RECRUITING","sponsor":"Biofabri, S.L","startDate":"2022-10-17","conditions":"Tuberculosis","enrollment":7120},{"nctId":"NCT04351685","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2020-11-09","conditions":"Mycobacterium Tuberculosis Infection","enrollment":6940},{"nctId":"NCT04538911","phase":"PHASE1","title":"Phase I Clinical Protocol for Pre-evaluation of the Safety of BCG-PPD in Tuberculosis Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2021-07-02","conditions":"Tuberculosis","enrollment":60},{"nctId":"NCT04106115","phase":"PHASE1, PHASE2","title":"DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr","status":"RECRUITING","sponsor":"University College, London","startDate":"2022-03-25","conditions":"Bladder Cancer","enrollment":64},{"nctId":"NCT03582085","phase":"PHASE2","title":"Phase II Clinical Trial: Multi-dosing the BCG Vaccine for Fibromyalgia","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2026-01-01","conditions":"Fibromyalgia","enrollment":""},{"nctId":"NCT04348370","phase":"PHASE4","title":"BCG Vaccine for Health Care Workers as Defense Against COVID 19","status":"COMPLETED","sponsor":"Texas A&M University","startDate":"2020-04-20","conditions":"Coronavirus, Coronavirus Infection, Coronavirus as the Cause of Diseases Classified Elsewhere","enrollment":659},{"nctId":"NCT04387461","phase":"PHASE2","title":"Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin","status":"COMPLETED","sponsor":"CG Oncology, Inc.","startDate":"2020-12-08","conditions":"Non Muscle Invasive Bladder Cancer","enrollment":35},{"nctId":"NCT06441110","phase":"PHASE3","title":"Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2023-06-01","conditions":"Urinary Bladder Neoplasms, BCG Vaccine, Immunotherapy, Active","enrollment":76},{"nctId":"NCT06427291","phase":"PHASE1","title":"Clinical Study of T3011 Intravesical Instillation for Treatment of NMIBC Patients","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-09-21","conditions":"Bladder Cancer","enrollment":20},{"nctId":"NCT05945498","phase":"PHASE1","title":"Evaluation of ТВ/Flu-05Е Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50 Years","status":"COMPLETED","sponsor":"Tatyana Zubkova","startDate":"2023-05-10","conditions":"Tuberculosis Infection","enrollment":51},{"nctId":"NCT06350838","phase":"PHASE1","title":"Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC)","status":"COMPLETED","sponsor":"Chengdu CoenBiotech Co., Ltd","startDate":"2022-11-11","conditions":"Non-muscular Invasive Bladder Cancer","enrollment":10},{"nctId":"NCT05626101","phase":"NA","title":"Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study","status":"UNKNOWN","sponsor":"Al-Azhar University","startDate":"2021-01-01","conditions":"Non-muscle-invasive Bladder Cancer","enrollment":280},{"nctId":"NCT04899765","phase":"PHASE4","title":"Measles and BCG Vaccines for Mother and Child","status":"RECRUITING","sponsor":"Bandim Health Project","startDate":"2021-05-20","conditions":"Vaccine Preventable Disease, Measles, Mother-Infant Interaction","enrollment":2400},{"nctId":"NCT03912207","phase":"PHASE1","title":"Investigating Immune Responses to Aerosol BCG Challenge in Healthy UK Adults","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2019-04-19","conditions":"Tuberculosis","enrollment":94},{"nctId":"NCT04496219","phase":"PHASE2","title":"Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-01-22","conditions":"Bladder Urothelial Carcinoma In Situ, Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8","enrollment":45},{"nctId":"NCT05284812","phase":"PHASE2","title":"A Phase Ⅱ Clinical Trial of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)","status":"SUSPENDED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2022-02-10","conditions":"Tuberculosis","enrollment":200},{"nctId":"NCT04659941","phase":"PHASE2","title":"Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers","status":"UNKNOWN","sponsor":"Universidade Federal do Rio de Janeiro","startDate":"2020-10-01","conditions":"COVID 19 Vaccine","enrollment":752},{"nctId":"NCT04563273","phase":"PHASE1","title":"Clinical Study of BCG Vaccine for Intradermal Injection","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2020-10-21","conditions":"Tuberculosis","enrollment":160},{"nctId":"NCT03180359","phase":"NA","title":"Vaccines Immunogenicity in Renal, Hepatic, Cardiac or Pulmonary Transplanted Children","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2016-01-01","conditions":"Transplantation","enrollment":55},{"nctId":"NCT01838200","phase":"PHASE1","title":"Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma","status":"TERMINATED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2014-03","conditions":"Metastatic Melanoma","enrollment":5},{"nctId":"NCT00070070","phase":"PHASE1","title":"Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2003-10-28","conditions":"Transitional Cell Carcinoma","enrollment":6},{"nctId":"NCT04537663","phase":"PHASE4","title":"Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2020-09-07","conditions":"Respiratory Tract Infections, Covid19","enrollment":6112},{"nctId":"NCT04475302","phase":"PHASE3","title":"BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots","status":"COMPLETED","sponsor":"Tuberculosis Research Centre, India","startDate":"2020-07-01","conditions":"COVID","enrollment":2175},{"nctId":"NCT04593771","phase":"PHASE1","title":"Phase I Clinical Protocol of BCG-PPD in Healthy People","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2020-10-21","conditions":"Tuberculosis","enrollment":80},{"nctId":"NCT02504203","phase":"PHASE4","title":"Can Earlier BCG Vaccination Reduce Early Infant Mortality? A Randomised Trial","status":"TERMINATED","sponsor":"Bandim Health Project","startDate":"2015-11","conditions":"Infant Mortality, BCG","enrollment":2332},{"nctId":"NCT04379336","phase":"PHASE3","title":"BCG Vaccination for Healthcare Workers in COVID-19 Pandemic","status":"COMPLETED","sponsor":"TASK Applied Science","startDate":"2020-05-04","conditions":"COVID-19, Sars-CoV2","enrollment":1000},{"nctId":"NCT02009332","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer","status":"COMPLETED","sponsor":"Aadi Bioscience, Inc.","startDate":"2014-04-09","conditions":"Non-muscle Invasive Bladder Cancer (NMIBC)","enrollment":21},{"nctId":"NCT04414267","phase":"PHASE4","title":"Bacillus Calmette-guérin Vaccination to Prevent COVID-19","status":"COMPLETED","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2020-05-26","conditions":"COVID-19, Virus Diseases, Corona Virus Infection","enrollment":301},{"nctId":"NCT02712424","phase":"PHASE2","title":"DAR-901 TB Booster Vaccine to Prevent TB in Adolescents","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2016-03","conditions":"Tuberculosis","enrollment":625},{"nctId":"NCT04632537","phase":"PHASE3","title":"BCG Vaccination to Prevent COVID-19","status":"WITHDRAWN","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2020-12-07","conditions":"COVID-19","enrollment":""},{"nctId":"NCT03296423","phase":"PHASE4","title":"Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly","status":"COMPLETED","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2017-09-21","conditions":"Infection, Hospitalization, Mortality","enrollment":200},{"nctId":"NCT03213405","phase":"PHASE1","title":"A Study to Assess Safety, Tolerability and Immunogenicity of the Live Attenuated hRSV Vaccine rBCG-N-hRSV","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2017-06-27","conditions":"Respiratory Syncytial Virus Infections","enrollment":24},{"nctId":"NCT04648800","phase":"PHASE3","title":"Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland","status":"UNKNOWN","sponsor":"Hanna Czajka","startDate":"2020-07-07","conditions":"Covid19, BCG Vaccination Reaction, SARS-CoV Infection","enrollment":1000},{"nctId":"NCT04350931","phase":"PHASE3","title":"Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2020-04-20","conditions":"Coronavirus Disease (COVID-19)","enrollment":900},{"nctId":"NCT02010203","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT","status":"TERMINATED","sponsor":"Heat Biologics","startDate":"2013-12","conditions":"Bladder Cancer","enrollment":104},{"nctId":"NCT01868464","phase":"PHASE1","title":"Challenge Model for Assessment of Human TB Immunity","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-05-28","conditions":"Tuberculosis","enrollment":92},{"nctId":"NCT02075203","phase":"PHASE2","title":"Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents","status":"COMPLETED","sponsor":"Aeras","startDate":"2014-02","conditions":"Tuberculosis","enrollment":989},{"nctId":"NCT03175380","phase":"EARLY_PHASE1","title":"Biological Samples Obtained by Leukapheresis Induced by Two BCG Vaccinations in BCG-naïve Healthy Adults in the US","status":"COMPLETED","sponsor":"Aeras","startDate":"2017-08-08","conditions":"Tuberculosis","enrollment":15},{"nctId":"NCT02471495","phase":"PHASE3","title":"RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE)","status":"WITHDRAWN","sponsor":"Medical Enterprises Europe B.V.","startDate":"2016-09","conditions":"Bladder Cancer","enrollment":""},{"nctId":"NCT03477448","phase":"PHASE4","title":"The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-04-01","conditions":"Warts","enrollment":40},{"nctId":"NCT02769923","phase":"NA","title":"ID Administration of fIPV Using Intradermal Adapters vs. BCG Syringe","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2015-09","conditions":"IPV","enrollment":450},{"nctId":"NCT01200992","phase":"PHASE3","title":"Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer","status":"TERMINATED","sponsor":"Bioniche Life Sciences Inc.","startDate":"2010-11","conditions":"Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma","enrollment":84},{"nctId":"NCT02389322","phase":"PHASE2","title":"Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2015-03","conditions":"Tuberculosis","enrollment":1044},{"nctId":"NCT02420444","phase":"PHASE1","title":"A Study for Safety and Immunogenicity of BCG and AERAS-404 in HIV-Negative, TB-Negative, BCG-Naive Adults","status":"COMPLETED","sponsor":"Aeras","startDate":"2011-01","conditions":"Tuberculosis","enrollment":70},{"nctId":"NCT02333474","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Mix Vaccine in Lung Carcinoma Patient","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2015-01","conditions":"Lung Neoplasms","enrollment":20},{"nctId":"NCT01729663","phase":"PHASE2, PHASE3","title":"Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients","status":"UNKNOWN","sponsor":"Laboratorio Pablo Cassará S.R.L.","startDate":"2009-04","conditions":"Cutaneous Melanoma","enrollment":108},{"nctId":"NCT01049282","phase":"PHASE1","title":"A Safety and Immunogenicity Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31)","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2008-12","conditions":"Tuberculosis","enrollment":39},{"nctId":"NCT00929396","phase":"PHASE1","title":"A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis (TB) Subunit Vaccine in Purified Protein Derivative (PPD) Positive Volunteers","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2007-09","conditions":"Tuberculosis","enrollment":20},{"nctId":"NCT01013623","phase":"PHASE3","title":"Stage IV Surgery Versus Best Medical Therapy","status":"TERMINATED","sponsor":"Saint John's Cancer Institute","startDate":"2009-11","conditions":"Stage IV Resectable Melanoma","enrollment":12},{"nctId":"NCT00633204","phase":"PHASE2","title":"Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer","status":"UNKNOWN","sponsor":"Iwate Medical University","startDate":"2008-02","conditions":"Bladder Cancer","enrollment":150},{"nctId":"NCT01250249","phase":"PHASE3","title":"A Study of Comparing Safety and Reactogenicity, of Lyophilized BCG Vaccine IP of Green Signal Bio Pharma Private Limited, India With BCG Vaccine of Serum Institute of India Limited in 120 Healthy Children.","status":"COMPLETED","sponsor":"Green Signal Biopharma Private Limited","startDate":"2008-11","conditions":"Healthy","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BCG for Injection","genericName":"BCG for Injection","companyName":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","companyId":"suzhou-suncadia-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BCG (Bacillus Calmette-Guérin) is a live attenuated mycobacterial vaccine that stimulates the immune system to recognize and attack cancer cells, particularly in the bladder. Used for Non-muscle-invasive bladder cancer (NMIBC), high-grade or recurrent, Carcinoma in situ (CIS) of the bladder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}